It is amazing what happens when we stop treating a rapidly lethal bacterial infection as a character-building exercise and start preventing it.
Welcome to “Remember When Kids Just Died?” A daily two-part tour through every vaccine-preventable disease, starting with polio on September 1, 2026. Each disease gets two posts: the pre-vaccine era, when parents enjoyed the character-building experience of burying their children, and the post-vaccine era, when we ruined everything by making childhood survivable. Cramming both into one post felt disrespectful, to the corpses and the Nobel Prizes.
Meningococcal disease has become much less common in the United States than it was in the 1990s. That decline began before routine adolescent MenACWY vaccination, but the drop in vaccine-covered serogroups accelerated substantially after the program began—because sometimes an intervention that prevents disease actually prevents disease.
The Numbers Ruined the Drama
The United States recommended routine MenACWY vaccination for adolescents in 2005, followed by a booster recommendation at age 16 in 2010. The vaccine targets serogroups A, C, W, and Y—notably, not every meningococcal strain ever invented by bacteria in their ongoing quest to be terrible. National meningococcal disease incidence fell from 0.61 cases per 100,000 people in 2000–2005 to 0.15 per 100,000 in 2011–2017. That is roughly a 75% decline in the overall rate, although the full decrease cannot be assigned to vaccination alone because disease rates were already falling.
Among the adolescents the program was designed to protect, the evidence is far less coy: disease caused by serogroups C, W, and Y dropped 88.8% in 11- to 15-year-olds and 77.2% in 16- to 22-year-olds during the post-booster era, compared with the pre-vaccine period.
The Vaccine Did Its Job
In vaccinated age groups, the annual rate of decline in C, W, and Y disease accelerated about twofold to threefold after MenACWY introduction. States with higher vaccine coverage generally had larger declines—which is awkward only if one is deeply committed to pretending coverage does not matter.
Researchers estimated that MenACWY vaccination prevented 222 adolescent cases caused by serogroups C, W, and Y between 2006 and 2017. Because every “case” is a potential death, amputation, neurologic injury, ICU admission, or devastated family—not merely a dot on a public-health graph—that number matters.
The importance of the booster is not bureaucratic decoration. Protection from a single MenACWY dose wanes over time, which is precisely why the second dose is recommended at age 16, when adolescents remain at elevated risk.
Rare Is Not Gone
Now for the part that gets lost between “vaccines work” and “therefore nothing bad can ever happen again”: meningococcal disease still occurs. CDC reported 463 confirmed and probable U.S. cases in 2025 based on preliminary data—the second-highest annual total since 2013—and rates have risen sharply since 2021, driven largely by serogroup Y.
The disease remains most frequent in infants, with another peak in adolescence; among adolescents and young adults, rates are highest from ages 16 through 23. So, no, “I have never seen it” is not an epidemiologic argument. It may simply mean prevention and low incidence have spared your community the experience.
Vaccines do not prevent every case, and MenACWY does not protect against serogroup B. That is why clinicians still need to recognize fever, severe headache, neck stiffness, altered mental status, a rapidly spreading petechial or purpuric rash, or sepsis as emergencies—not as a chance to reassure everyone that it is “probably viral.”
And if anyone needs a reminder that “rare” is not synonymous with “gone,” England has provided one. A university outbreak this year occurred amid declining meningococcal vaccination coverage, with several reported deaths. Meningococcal disease has not become harmless; it has become less common where prevention is used consistently. Let vaccination rates slide, crowd young adults into dormitories, add the usual sharing of respiratory secretions and terrible sleep habits, and bacteria will happily remind everyone why public-health programs existed in the first place.
The Actual Takeaway
Before widespread vaccination, pediatricians saw meningococcal disease more often and knew its aftermath too well: children who died, children with brain injury or hearing loss, and children who survived only after amputations caused by fulminant septic shock. After vaccination, we see far less of that devastation. Not zero—because biology refuses to be that considerate—but far less. That is not a coincidence, a wellness trend, or the triumph of vague optimism. It is what prevention looks like.
Sources
Centers for Disease Control and Prevention. Meningococcal Disease Surveillance and Trends. Updated June 2026.
Mbaeyi S, et al. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States. JAMA Pediatrics. 2020.